多发性骨髓瘤患者血浆miR-17-3p表达及其临床意义  

Expression and clinical significance of plasma miR-17-3p in patients with multiple myeloma

作　　者：刘海军[1] 王莉莉[1] 李言飞[2] 孙勇[2] LIU Haijun;WANG Lili;LI Yanfei;SUN Yong(Department of Hematology,Yantai Laiyang Central Hospital,Laiyang 265200,China;Laboratory,Yantai Laiyang Lentral Hospital,Laiyang 265200,China)

机构地区：[1]烟台市莱阳中心医院血液病科,山东莱阳265200 [2]烟台市莱阳中心医院检验科,山东莱阳265200

出　　处：《中华实用诊断与治疗杂志》2020年第6期596-599,共4页Journal of Chinese Practical Diagnosis and Therapy

基　　金：山东省医药卫生科技发展计划项目(2016WS0302)。

摘　　要：目的探讨多发性骨髓瘤(multiple myeloma,MM)患者血浆miR-17-3p的表达及其临床意义。方法90例MM患者为MM组,30例其他血液疾病患者为非MM组,30例体检健康者为对照组;采用实时荧光定量PCR法检测3组血浆miR-17-3p相对表达量,分析MM患者血浆miR-17-3p相对表达量与临床病理特征的关系;以血浆miR-17-3p相对表达量均值3.125为临界值,将MM患者分为高表达(miR-17-3p≥3.125)组43例和低表达(miR-17-3p<3.125)组47例,采用Kaplan-Meier生存分析法分析不同miR-17-3p相对表达量患者的预后情况。结果MM组血浆miR-17-3p相对表达量(3.125±0.710)高于非MM组(1.205±0.353)和对照组(1.146±0.261)(P<0.05),非MM组与对照组比较差异无统计学意义(P>0.05)。ISS分期Ⅲ期MM患者血浆miR-17-3p相对表达量(3.707±0.715)高于Ⅱ期(3.079±0.713)和Ⅰ期(2.915±0.708)患者(P<0.05),Ⅱ期患者高于Ⅰ期患者(P<0.05),不同年龄、性别、DS分期、诊断分型、血清乳酸脱氢酶、血钙及血红蛋白水平患者血浆miR-17-3p相对表达量比较差异均无统计学意义(P>0.05)。高表达组患者3年总体生存率(25.6%)低于低表达组(65.9%)(P<0.05)。结论MM患者血浆miR-17-3p表达升高,与ISS分期和患者不良预后有关,有可能成为新的MM肿瘤标志物。Objective To investigate the expression and clinical significance of plasma miR-17-3 p in patients with multiple myeloma(MM).Methods The expressions of plasma miR-17-3 p were detected by real-time fluorescence quantitative PCR in 90 MM patients(MM group),30 patients with other blood diseases(non-MM group)and 30 healthy volunteers(control group).The relationships between the relative expression of miR-17-3 p and clinical pathological characteristics were analyzed in MM group.With the mean miR-17-3 p level of 3.125 as the critical value,MM group was redivided into 43 patients with miR-17-3 p≥3.125(high-expression group)and 47 patients with miR-17-3 p<3.125(low-expression group).Kaplan-Meier survival analysis was used to predict the prognosis of patients with different relative expressions of miR-17-3 p.Results The relative expression of miR-17-3 p was higher in MM group(3.125±0.710)than that in non-MM group(1.205±0.353)and control group(1.146±0.261)(P<0.05),and showed no significant difference between non-MM group and control group(P>0.05).The relative expression of miR-17-3 p was higher in patients with ISS stageⅢ(3.707±0.715)than that in stageⅡ(3.079±0.713)andⅠ(2.915±0.708)(P<0.05),was higher in stageⅡthan that in stageⅠ(P<0.05),and showed no significant differences in patients with different age,gender,DS stage,diagnostic typing,serum lactate dehydrogenase,blood calcium and hemoglobin levels(P>0.05).The 3-year overall survival rate was lower in high-expression group(25.6%)than that in low-expression group(65.9%)(P<0.05).Conclusion The increased expression of plasma miR-17-3 p in MM patients is correlated with ISS stage and poor prognosis,and it might be a new tumor marker for MM.

关 键 词：多发性骨髓瘤 miR-17-3p 预后 分期 

分 类 号：R733.3[医药卫生—肿瘤]